Avecho Biotechnology Limited
AVEFF
Get informed when a big investor buys or sells
+ FollowMarket Cap$61.82M
Close$
$-0.00
162.2% downside
Current Fair Value
162.2% downsideOvervalued by 162.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $61.82 Million |
|---|---|
| Enterprise Value | $55.45 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0 |
| Beta | 1.13 |
| Outstanding Shares | 3,717,986,625 |
Return
| Return on Equity | -382.39% |
|---|---|
| Return on Assets | -86.72% |
| Return on Invested Capital | -135.86% |
Valuation & Multiples
| P/E Ratio | -10.67 |
|---|---|
| PEG | 37.8 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 26.19 |
| Enterprise Value to EBIT | -5.93 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 24, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
March 3, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Avecho Biotechnology Limited
9 employees
CEO: Paul Gavin Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and Ind...